Radforsk has granted seven research projects a total amount of MNOK 1,25 to further develop exciting research projects within photodynamic treatment and photochemical internalization.
Radforsk is an evergreen investor focusing on companies that develop cancer treatments.
“Radforsk has ploughed NOK 200 million of its profit back into cancer research at Oslo University Hospital. Of these, NOK 25 million, have gone to research in PDT/PCI. This year we grant seven projects a total of NOK 1,25 million,” says Jónas Einarsson, CEO of Radforsk.
Radforsk had received a total of seven applications by the deadline on 1 March. All projects were allocated funding.
The applications have been assessed by external experts.
The researchers who have received funding for PDT/PCI research in 2020 are:
- Anette Weyergang is granted NOK 300 000 to the project: “Photochemical Internalization: Development of a novel tumor-specific protein toxin to defeat aggressive and resistant cancers”
- Beáta Grallert is granted NOK 100 000 for the project: “Cancer-specific bioluminescence-PDT”
- Judith Jing Wen Wong is granted NOK 100 000 to the project “Light-enhanced delivery of PD-L1-targeting immuntoxin”
- Kirsten Sandvig and Tore Geir Iversen are granted NOK 200.000 to the project “Drug-loaded Photosensitizer-Chitoscan Nanoparticles for cominatorial Chemo- and Photodynamic cancer therapy”
- Mouldy Sioud is granted NOK 200.00 to the project “Antibody- and peptide-targeted photodynamic therapy to kill cancer cells”
- Qian Peng and Henry Hirschberg are granted NOK 50 500 to the project “Improved therapy of brain tumors by PDT induced anti-tumor immune responses”
- Qian Peng is granted 300 000 to the project “Photopheresis of patients with Crohn’s disease using 5-aminolevulinic acid”
Cancer research in the field of photodynamic therapy and photochemical internalisation studies the use of light in direct cancer treatment in combination with drugs, or to deliver drugs that can treat cancer to cells or organs.
Since its formation in 1986, Radforsk has generated NOK 600 million in fund assets and channelled NOK 200 million to cancer research, based on a loan of NOK 1 million in equity back in 1986.
During this period, NOK 200 million have found its way back to the researchers whose ideas Radforsk has helped to commercialise.
NOK 25 million have gone to research in photodynamic therapy (PDT) and photochemical internalisation (PCI). In total, NOK 40 million will be awarded to this research.